Results 31 to 40 of about 457,473 (371)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 [PDF]

Leukemia, 2020
La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34:1805–15. https://doi.org/10.1038/s41375-020-0891-0. CAS Article PubMed Google Scholar Download references Division of Hematology, University of Siena, Siena, Italy ...
Alessandro Gozzetti, Enrico Capochiani, Monica Bocchia   +2 more
openalex   +5 more sources

Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor [PDF]

Tzu Chi Medical Journal, 2019
Polycythemia vera (PV) is relatively uncommon in early adulthood, and evidence about the prevalence of the Janus kinase 2 (JAK2) V617F mutation in the general population is limited.
Shang-Hsien Yang, Hsiang-Lin Wan, Ming-Hui Gu, Tso-Fu Wang   +3 more
doaj   +2 more sources

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study [PDF]

The Lancet Haematology, 2017
Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Ramón V. Tiu, Pierre Zachée, Éric Jourdan, Elliott F. Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa   +15 more
openalex   +2 more sources

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy. [PDF]

Inflamm Res
Chen P, Long J, Zhang J, Xie F, Wu W, Tian Z, Zhang S, Yu K.   +7 more
europepmc   +3 more sources

Covalent Modification of the JH2 Domain of Janus Kinase 2. [PDF]

ACS Med Chem Lett, 2022
Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to evaluate JH2 domains as therapeutic targets. The JH2 domains of three Janus kinases (JAK1, JAK2, and TYK2) possess a cysteine residue in the catalytic ...
Henry SP, Liosi ME, Ippolito JA, Menges F, Newton AS, Schlessinger J, Jorgensen WL.   +6 more
europepmc   +3 more sources

The methyl-CpG binding domain 2 regulates peptidylarginine deiminase 4 expression and promotes neutrophil extracellular trap formation via the Janus kinase 2 signaling pathway in experimental severe asthma. [PDF]

Ann Med
Peng B, Yan MY, Chen YR, Sun F, Xiang XD, Liu D.   +5 more
europepmc   +2 more sources

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.

Cochrane Database of Systematic Reviews, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
A. Martí-Carvajal, Vidhu Anand, I. Solá   +2 more
semanticscholar   +5 more sources

Janus kinase inhibitors - their current applications and future prospects [PDF]

Farmacja Polska, 2022
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska, Karolina Żurawska, Maciej Arciszewski, Arnold Kukowka, Bolesław Banach   +4 more
doaj   +1 more source

Thiamine transporter 2 and Janus kinase 2 inhibitor, fedratinib suppresses thermogenic activation of human neck area-derived adipocytes. [PDF]

Front Endocrinol (Lausanne)
Karadsheh G, Kovács E, Alrifai R, Seo M, Győry F, Csatári-Kovács R, Csősz É, Póliska S, Fésüs L, Arianti R, Kristóf E.   +10 more
europepmc   +3 more sources

Tyrosine Kinase 2 and Janus Kinase‒Signal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis.

Journal of American Academy of Dermatology, 2021
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase‒signal transducer and activator of transcription (JAK-STAT) pathway plays a major role in intracellular cytokine signaling in inflammatory processes ...
J. Krueger, I. McInnes, A. Blauvelt
semanticscholar   +1 more source